PIK3CA and cancer: PIK3CA is indeed most frequently mutated in breast cancer (28.8%), principally in estrogen receptor (ER)-positive carcinomas (38.9%), as well as endometrium (27.4%) and urinary tract (20.2%) cancers [51].